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Health related quality of life in SCALOP, a randomized phase II trial comparing 
chemoradiotherapy regimens in locally advanced pancreatic cancer (LAPC) 
 
Summary  
 
SCALOP was a randomized, phase II trial in which patients with locally advanced, 
inoperable, pancreatic cancer were given capecitabine or gemcitabine based 
chemoradiation. This paper reports the health related quality of life (HRQL) data, 
including validation of the QLQ-PAN26 tool in CRT. The data support the use of 
chemoradiation as a treatment option (with capecitabine-based chemoradiation 
preferred) and the use of the QLQ-PAN26 as a valid tool. 
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Abstract  
Purpose/Objective(s) 
Chemoradiotherapy (CRT) for patients with LAPC provides survival benefits but may 
result in considerable toxicity. Health-related quality of life (HRQL) measures during 
CRT have not been widely reported. This paper reports HRQL data from the 
SCALOP trial, including validation of the QLQ-PAN26 tool in CRT.  
Methods and Materials  
Patients with locally advanced, inoperable, non-metastatic carcinoma of the pancreas 
were eligible. Following 12 weeks of induction gemcitabine plus capecitabine 
(GEMCAP) chemotherapy, patients with stable/responding disease were randomised 
to a further cycle of GEMCAP followed by capecitabine or gemcitabine based CRT.  
HRQL was assessed with the EORTC QLQ-C30 and PAN26. 
Results   
114 patients from 28 UK centres were registered and 74 patients randomized. There 
was improvement in the majority of the HRQL scales during induction chemotherapy. 
Significant deterioration in fatigue, appetite loss, and gastrointestinal symptoms 
during CRT recovered within 3 weeks following CRT. Differences in changes in 
HRQL scores between trial arms rarely reached statistical significance, however 
where they did, they favoured capecitabine. PAN26 scales had good internal 
consistency and were able to distinguish between subgroups of patients experiencing 
toxicity 
Conclusions  
Although there is deterioration in HRQL following CRT this resolves within 3 weeks. 
HRQL data support the use of capecitabine over gemcitabine-based chemoradiation. 
The QLQ-PAN26 is a reliable and valid tool to use in patients receiving CRT. 
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Introduction 
 
Pancreatic cancer has a 5-year survival of less than 5% [1]. Treatment with 
chemoradiotherapy (CRT) may improve overall survival in patients with locally 
advanced inoperable tumours but may result in considerable toxicity.[2]. Health-
related quality of life (HRQL) measures, not widely reported in the literature, are 
therefore relevant when interpreting trial data and in making treatment 
recommendations for patients with advanced pancreatic cancer.  
 
SCALOP (Selective Chemoradiation in Advanced Localised Pancreatic Cancer) was a 
randomized phase II trial that compared gemcitabine based CRT (Gem-CRT) and 
capecitabine based CRT (Cap-CRT) following a course of induction chemotherapy in 
locally advanced pancreatic cancer (LAPC). SCALOP demonstrated that Gem-CRT 
was associated with more CTCAE grade 3/4 haematological and non-hematological 
toxicities and inferior median survival (13.4 vs 15.2 months, p=0.012) [3]. In 
SCALOP, HRQL was assessed with EORTC QLQ-C30 [4] and the pancreatic cancer 
module, the EORTC QLQ-PAN26 [5] which was developed for patients undergoing 
surgery, palliative chemotherapy and endoscopic treatment of pancreatic cancer; 
however it has not been previously validated in CRT. 
 
This paper describes generic, disease- and treatment-specific HRQL during and after 
treatment with CRT. It also provides validation and reliability data on the QLQ-
PAN26 in patients receiving CRT.  
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Methods and materials 
 
Participants and methods 
SCALOP was a multi-centre, open-label, randomised, parallel, two-arm, phase II trial 
conducted in the UK [3].  Patients with locally advanced, inoperable non-metastatic, 
histologically confirmed carcinoma of the pancreas were eligible. Registered patients 
received 3 cycles of gemcitabine and capecitabine (GemCap) chemotherapy and then 
restaged with CT scan of thorax, abdomen and pelvis. Patients with stable or 
responding disease (RECIST criteria, version 1.1), tumour diameter 6 cm or less and 
WHO performance status 0-1 were randomised 1:1 to either Gem-CRT or Cap-CRT 
by stratified minimisation with a random element (80:20). All participants provided 
written informed consent. The study was approved by the UK Medical Research and 
Ethics Committee (MREC) and the UK Medicines and Healthcare products 
Regulatory Agency (MHRA). This study was registered at ISRCTN, number 
96169987. The full protocol can be accessed at: 
http://www.wctu.org.uk/publications/scalop/SCALOP%20Clinical%20Protocol%20v
4.0.pdf. 
 
Treatment protocol 
Induction chemotherapy consisted of 3 cycles of gemcitabine (1000mg/m2 
intravenously over 1 hr on days 1, 8 and 15 of a 28 day cycle) and capecitabine 
(830mg/m2 orally, twice daily on days 1-21 of a 28 day cycle). Randomised patients 
received a further cycle of GemCap followed by concurrent chemoradiotherapy in 
combination with either gemcitabine (300mg/m2 once per week) or capecitabine 
(830mg/m2 twice daily on days of radiotherapy only). The total radiotherapy dose was 
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50.4Gy in 28 daily fractions over 5.5 weeks by use of 3D conformal or intensity 
modulated radiotherapy planning. No subsequent adjuvant therapy was given. 
 
Health related quality of life 
Health-related quality of life was assessed using the HRQL generic measure, the 
EORTC QLQ-C-30 [which assesses global quality of life, functional domains 
(physical, emotional, social, role and cognitive) and symptoms (fatigue, nausea and 
vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea, financial 
difficulty) that commonly occur in patients with cancer] [4] and a disease specific 
measure, the EORTC QLQ-PAN26 (pancreatic domain – which uses 26 questions 
hypothesised as 17 scales and single items specifically related to pancreatic disease 
symptoms, treatment side-effects and emotional issues) [5]. Patients self-completed 
paper questionnaires at 6 time points – week 0 (baseline), week 17 (post induction 
chemotherapy), week 23 (immediately post-CRT) and subsequently at follow-up 
(weeks 26, 39 and 52) even, where possible, if patients experienced disease 
progression. Questionnaires were included if completed within 1 week (4 weeks for 
week 39 and 52) of the specified time point. The EORTC standard scoring procedure 
is that function scales and items are defined such that higher scores represent better 
HRQL whilst symptom scales and items are defined such that higher scores indicate 
more symptoms (worse HRQL). The full list is reported in Table 1.  
 
Data analysis 
All randomised patients were included in the analysis. The analyses were pre-
specified in the statistical analysis plan and performed on an intention to treat basis 
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[3]. All analyses were undertaken and graphs produced using STATA® statistical 
software version 13.0 (Stata Corp., College Station, Texas, USA). 
 
Data were imputed according to EORTC guidance if less than half the items within a 
scale were missing [6]. Where data were missing from more than half the items within 
any scale, these scales were excluded from the analyses. When a complete 
questionnaire was missing, the reason for the missing questionnaire was ascertained 
and categorized.  
 
We performed two sets of analyses, one looked at the change in HRQL during 
induction chemotherapy (week 0 to week 17) and the other looked at the change from 
start of CRT (week 17) and later time points to assess the specific impact of CRT on 
HRQL  and difference between arms. 
 
The changes in mean HRQL between earlier and later time-points in all patients was 
normally distributed (assessed using Shapiro–Wilk tests for normality) and were 
presented with mean scores at each time-point, changes in mean scores and 95% 
confidence intervals around those changes.  Changes in scores of 10 or more points 
were considered clinically significant [7]. When this data was split by treatment arm 
to compare changes in HRQL during and after CRT, the data was no longer normally 
distributed and therefore Wilcoxon rank sum tests were used to compare changes 
between arms. We had no a priori hypotheses as to which specific scales would be 
most affected by which arm so we compared all scales and highlighted results at the 
p<0.05 level (and p<0.01 to reduce errors from multiple testing) in these exploratory 
analyses. 
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Psychometric testing of the QLQ-PAN26 
Cronbach’s alpha coefficient was calculated as a measure of reliability of the QLQ-
PAN26 using data from the week 23 assessments. Cronbach’s alpha measures inter-
correlation between the test scores of related items within the scales and alpha value ≥ 
0.70 indicates good consistency [8]. Construct validity was assessed by observed 
differences in the scales at the time point immediately after CRT (week 23) between 
the group of patients who had any CTCAE grade 3 or 4 adverse event recorded by 
nurses and those who did not. It was hypothesised that patients with grade 3 or 4 
adverse events would report worse scores in more scales than patients without any 
events. Additional known group comparisons were made in the ‘side effects scale’ 
between patients with and without a Serious Adverse Reaction (SAR) persisting at the 
week 23 time point where symptoms are typically most severe. SARs were defined as 
serious adverse events with at least possible causal relationship to one of the trial 
medications (including radiotherapy). 
 
Role of funding source 
The study was funded by Cancer Research UK’s Clinical trials Awards and Advisory 
Committee (CRUK 07/040) who had no role in study design, data collection, analysis 
or interpretation, or writing of this report.  
 
Results 
Between Dec 24, 2009 and Oct 25, 2011, 114 patients were registered into the trial 
from 28 hospitals across the UK. All patients were followed until progression, death 
or 12 month follow-up assessment. 74 patients were eligible for randomisation after 3 
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cycles of induction chemotherapy; 38 were allocated to receive Gem-CRT and 36 to 
receive Cap-CRT [3]. HRQL data from patients who failed to proceed to 
randomisation after induction are not included in this analysis because very few 
patients completed the questionnaire after disease progression. 
 
Questionnaire compliance and missing data 
Questionnaire compliance was good throughout the study, baseline data being 
available for 34 (94%) of 36 patients receiving Cap-CRT and 35 (92%) of 38 patients 
receiving Gem-CRT (Table 2a). Rates at the 39-week time point were reduced to 71% 
(Cap-CRT arm) and 66% (Gem-CRT arm). Importantly, fewer questionnaires were 
returned in the Gem-CRT arm during later time-points due to higher rates of 
progression and death. Details and reasons for missing questionnaires are shown in 
Table 2a. Table 2b suggests that those with missing questionnaires at later timepoints 
(particularly week 26 and 39) had worse overall survival than those who did complete 
questionnaires. No problems were reported regarding patients completing the 
questionnaires but Table 3 suggests that the scale on sexual satisfaction on the QLQ-
PAN26 questionnaire was not completed as often as other scales. The reason for non-
return was missing for more patients at week 23 compared to other weeks. The week 
23 assessment involved a clinic visit that was not part of standard care and a number 
of centres did not return any CRFs for this timepoint so we cannot ascertain for 
certain the reason for non-completion although it is likely to be administration error.  
 
We received 305 questionnaires from all patients across all timepoints. Only 8 of the 
32 HRQL scales had at least one missing item in more than 3% of the 305 
questionnaires. Of those 8 scales, 7 had at least one missing item in less than 7% of 
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the 305 questionnaires. The other scale, sexual dissatisfaction, had at least one 
missing item in 24% of the 305 questionnaires. Only those scales with more than at 
least half of the items completed could be imputed using the EORTC method – thus 
only one (sexual dissatisfaction) of the 32 scales had more than 3% of values imputed 
using the EORTC method. 
 
Data from the 52 week follow up has been omitted from the further analyses due to 
the low return rate. 
 
HRQL during induction chemotherapy (weeks 0-17) 
Baseline scores for functional scales were all greater than 64, similar to findings in 
other studies of pancreatic cancer. The range of possible scores is 0-100; our 
unpublished data show median scores for function scales of 90-100 in patients with 
symptomatic gallstones and in a sample of normal individuals (C Johnson, 
unpublished data). Baseline scores for all symptom scores were below 50 except for 
future health concern (mean 58.18). For comparison, patients with symptomatic 
gallstones score their pain around 50, and normal individuals <5 (C Johnson, 
unpublished data). 
 
Figure 2 and Table 3 show that, for all randomised patients, the mean changes in the 
majority of scales show improvement during induction chemotherapy with clinical 
significance achieved in the pain (-11.02; 95% CI: -18.08 to -3.96), appetite loss (-
13.56; 95% CIs: -23.90 to -3.22), pancreatic pain (-14.32; 95% CI: -21.02 to -7.62), 
weight loss (-10.34; 95% CIs: -20.62 to -0.06), and future health (-10.30; 95% CIs: -
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18.78 to -1.83) scales. QLQ-PAN26 questions relating to side effects from treatment 
indicated significant deterioration (14.97; 95% CIs: 5.38 to 24.55). 
 
HRQL during and after CRT  
Figure 3 and Table 4 show the mean changes in scale scores between week 17 (start 
of CRT) and later time-points of week 23 (at the end of CRT), week 26 (3 weeks 
post CRT), and week 39. Most scales deteriorated between the start (week 17) and 
end (week 23) of CRT. There was clinically significant deterioration in fatigue 
(11.70; 95% CIs: 5.34-18.07), appetite loss (19.57; 95% CIs: 7.65-31.48), and 
gastrointestinal symptoms (12.22; 95% CIs: 2.83-21.61) and no clinically 
significant improvements over this period. However, there were no significant 
differences in mean scores between week 17 and week 26, suggesting that recovery 
from the acute effects of CRT occurs within a 3-week period. At week 39 
compared to week 17, there were clinically significant deteriorations in pain (10.96; 
95% CIs: 0.52-21.41) and bloating (10.81; 95% CIs; 0.99-20.63). 
 
HRQL by trial arm 
Table 5 suggests that, due to chance, there were some imbalances in HRQL scale 
median scores at week 17 (the point of randomisation) between arms. Thus changes 
in score from week 17 and each subsequent time point were compared rather than 
absolute scores at each time point. Table 5 also shows the difference between trial 
arms in terms of change in scale scores between week 17 and later time points. The 
median change between week 17 and later time points was never worse in the Cap-
CRT arm than in the Gem-CRT arm. The results of the Wilcoxon rank sum tests 
that compared the differences between changes in score suggest little difference 
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between arms but where differences were found, each favoured Cap-CRT. Between 
week 17 and 23 there were differences at the p<0.05 level between trial arms in the 
distribution of the change in the following scores: cognitive functioning (p=0.036), 
fatigue (p=0.046), bloating (p=0.035), and dry mouth (p=0.029). Between week 17 
and 26, this was only significant for future health (p=0.033). Between week 17 and 
39, this was significant for cognitive functioning (p=0.011), dry mouth (p=0.001), 
and body image (p=0.022). The only significant difference at the p<0.01 level was 
in dry mouth between week 17 and 39 (p=0.001). Graphs of these selected domains 
are shown in Figure 4.  
 
Validation of the QLQ-PAN26 questionnaire during CRT 
Cronbach’s alpha was >0.7 for all scales (implying good internal consistency) 
except for the jaundice scale (r=0.46). The jaundice scale has the following two 
questions: “have you had itching?” and “to what extent was your skin yellow?” The 
correlation between the scores for these two questions was low (Pearson’s 
correlation coefficient=0.37).  
 
Table 6 shows the mean scores at week 23 in the group of patients who had any 
CTCAE grade 3 and 4 adverse events during CRT (primarily gastrointestinal and 
constitutional) and those who did not. Clinically significant differences were seen 
in 8 scales (primarily gastrointestinal and constitutional) with worse scores in the 
patients with more severe adverse events. There was a significantly worse mean 
score at 23 weeks in the “side effects of treatment” scale when comparing those 
who had a SAR during CRT and those who did not: 34.9 (n=44; 95% CIs: 27.0-
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42.7) vs 50.0 (n=4; 95% CIs: -18.5-118.5) although the confidence intervals are 
wide due to the small numbers. 
 
 
Discussion 
In the SCALOP trial there was an improvement in the majority of the HRQL scales 
during induction chemotherapy. There was significant decline in a number of 
HRQL scales during CRT (fatigue, appetite loss, and gastrointestinal symptoms) 
but these recovered by 3 weeks after the end of CRT. We speculate that the 
clinically significant deteriorations in pain and bloating scores at week 39 is likely 
to have been due to disease progression, either clinical or sub-clinical – however, as 
only 6 patients with documented progression had HRQL recorded at week 39, this 
conclusion is conjectural. The exploratory comparisons of differences in HRQL 
scores between trial arms rarely reached statistical significance, however where 
they did, they all favoured Cap-CRT, providing support to our previously published 
data for the use of Cap-CRT rather than Gem-CRT.  
 
How does SCALOP compare with other HRQL trials in LAPC? In the E4201 study 
which randomized patients to single agent gemcitabine and gemcitabine based 
CRT, decline in HRQL scores were noted during CRT, which returned to baseline 
levels within 9 weeks of completion of CRT [9]. Despite a large difference in 
Grade 4 toxicity between the arms, there were no statistically significant 
differences in median FACT-Hep scale score between the treatment arms. This may 
have been due to small patient numbers, or due to separation in time of the toxicity 
and the HRQL assessment, so that the toxicity had resolved when HRQL was 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
recorded. Short et al reported HRQL using QLQ C30 and QLQ PAN26 
questionnaires from a single-arm study, which included LAPC (n=41) and post-
operative patients (n=22) receiving induction gemcitabine followed by 5FU-based 
CRT [10]. CRT improved local symptoms (pain scores and digestive symptoms) 
and the authors suggested that patients with local symptoms at baseline are most 
likely to benefit from CRT. Serrano et al reported HRQL outcomes from a single 
arm phase II trial of 2 cycles neo-adjuvant gemcitabine-oxaliplatin based CRT 
(30Gy in 15 fractions concurrent with first cycle) in patients with borderline 
resectable and resectable tumours (n=71) [11]. This study reported a decline in 
global HRQL scores but an improvement in pancreatic pain at the end of neo-
adjuvant treatment. Long-term outcome in the unresected population was not 
reported due to low rate of questionnaire return. Contrary to these studies, 
SCALOP showed a temporary deterioration in local symptoms following CRT, 
although improvements in local symptoms were seen during induction 
chemotherapy. 
 
The comparison of HRQL outcomes between LAPC patients treated with 
chemotherapy alone versus CRT remains an important, but unanswered, question. 
The clinical outcome from the LAP 07 trial, randomizing patients between 
chemotherapy alone and chemotherapy followed by induction chemotherapy, has 
been reported in abstract form only [12]. This study showed no additional overall 
survival benefit for CRT over and above chemotherapy alone, calling into question 
the role of CRT in this disease. No HRQL data was collected in this trial.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
This is the first study to validate the use of QLQ-PAN26 in patients receiving CRT, 
a treatment that was rarely used during its development. To our knowledge, the 
data presented here provide the most robust validation to date of the use of the 
QLQ-PAN26 in patients receiving CRT. Importantly, a range of scales and items 
showed deterioration between the start and end of CRT but with recovery by 3 
weeks after the end of CRT. This corresponds well with expected side effects of 
CRT and demonstrates the ability of PAN26 to detect clinically relevant changes. 
The scales showed good correlation with nurse reported adverse events and 
treatment related toxicities. Finally, the scales also showed good internal 
consistency with the exception of the jaundice scale. This is not surprising, as all 
patients were free of jaundice during treatment. 
 
Our study has several limitations. Patient numbers in each arm were relatively 
small resulting in wide confidence intervals and few of the observed differences 
achieve statistical significance. Also, when comparing arms, multiple tests were 
conducted which increased the probablity of obtaining a p value of less than 0.05 
by chance. Additionally, HRQL data from registered patients who did not proceed 
to randomisation were not captured, restricting the longitudinal trends shown to a 
cohort of chemotherapy-selected patients with stable or responding disease and 
therefore better overall prognosis. Importantly, questionnaire return rates continued 
to decline through the study period and it is likely those patients who did not 
respond to questionnaires during follow up experienced a different HRQL profile. 
This may be a source of bias, however data attrition is a significant problem in all 
studies of pancreatic cancer, largely due to the nature of the disease and patients’ 
frequent rapidly declining health. Our data collection rate compares favourably 
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with E4201 trial and Serrano et al where the HRQL questionnaire compliance was 
40% at 9 months and 25% at 6 months respectively [11].  
 
Despite these limitations, this study has confirmed the validity of the QLQ-PAN26 
in patients receiving CRT. It provides detailed insight into HRQL following 
induction chemotherapy and consolidation CRT, which has not been previously 
described elsewhere. These data will be useful when discussing therapeutic options 
in patients with LAPC and lend further support to the use of capecitabine rather 
than gemcitabine as the concomitant cytotoxic in this setting. Importantly, our data 
help to dispel any previously held anxieties and beliefs that CRT is a toxic 
treatment that will inevitably detract from HRQL in patients with limited life 
expectancy. The role of CRT in this disease remains controversial and future trials 
in LAPC should incorporate HRQL end-points. 
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Titles and footnotes for figures  
Figure 1. Flow diagram 
 
Figure 2. Changes in mean HRQL scores following induction chemotherapy (between 
week 0 and week 17) with 95% confidence intervals 
NB Negative score indicates deterioration in both functional and symptom scales. Abbreviations as shown in Table 
2. 
 
Figure 3. Changes in mean HRQL scores following chemo RT (week 17 to later time 
points) with 95% confidence intervals 
a. QLQ-C30 
b. QLQ-PAN26 
 
NB Negative score indicates deterioration in both functional and symptom scales. Abbreviations as shown in Table 
2. 
 
Figure 4. Changes in selected mean HRQL scores by treatment arm with 95% 
confidence intervals 
a. Cognitive functioning (high score indicates better QoL) 
b. Fatigue (low score indicates better QoL) 
c. Bloating (low score indicates better QoL) 
d. Dry mouth (low score indicates better QoL) 
e. Body image (low score indicates better QoL) 
f. Future health concerns (low score indicates better QoL) 
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Table 1. QLQ scales, abbreviations, and imputations  
 
Scale 
Abbreviation QLQ Items in scale Number of 
questionnaires 
with at least 
one item of the 
scale missing*  
Of those, 
number 
imputed by 
EORTC 
guidelines 
Global GQOL C30 2 2 0 
Functional      
Physical Physical C30 5 5 4 
Role Role C30 2 2 0 
Emotional Emotional C30 4 4 3 
Cognitive Cognitive C30 2 0 0 
Social Social C30 2 2 2 
Symptoms      
Fatigue Fatigue C30 3 4 3 
Nausea and vomiting Nausea C30 2 1 1 
Pain Pain C30 2 5 5 
Dyspnoea Dyspnoea C30 1 2 0 
Insomnia Insomnia C30 1 2 0 
Appetite loss Appetite C30 1 2 0 
Constipation Constipation C30 1 1 0 
Diarrhoea Diarrhoea C30 1 3 0 
Financial difficulties Financial C30 1 2 0 
Pancreatic pain Panc Pain PAN26 4 14 8 
Bloating Bloating PAN26 1 8 0 
Gastrointestinal Gastro PAN26 2 8 1 
Taste loss Taste PAN26 1 7 0 
Indigestion Indigestion PAN26 1 11 0 
Flatulence Flatulence PAN26 1 8 0 
Weight Weight PAN26 1 7 0 
Weak limbs Weak limbs PAN26 1 7 0 
Dry mouth Dry mouth PAN26 1 9 0 
Jaundice Jaundice PAN26 2 15 8 
Altered bowel habit Bowel PAN26 2 13 6 
Poor body image Image PAN26 2 11 3 
Side effects of treatment Side effects PAN26 1 21 0 
Future health concern Future PAN26 1 9 0 
Forward planning limited Planning PAN26 1 9 0 
Satisfaction with healthcare Healthcare PAN26 2 16 9 
Sexual dissatisfaction Sexual PAN26 2 72 14 
*Of the total of 305 questionnaires received from all patients across all timepoints 
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Table 2a. Questionnaire compliance and reasons for missing data by treatment group. 
 
  
RT + Capecitabine (n=36)   RT + Gemcitabine (n=38)   
  Baseline 17 week 23 week 26 week 39 week 52 week Baseline 17 week 23 week 26 week 39 week 52 week 
  
n % n % n % n % n % n % n % n % n % n % n % n % 
Patients still alive 36   36   35   35   34   29   38   38   37   36   29   24   
CRFs returned 34 94 31 86 23 66 24 69 24 71 19 66 35 92 30 79 26 70 27 75 19 66 13 54 
Reasons for non-return                                                 
Admin error 1 3 3 8 3 9 6 17 2 6 3 10 3 8 3 8 3 8 3 8 2 7 1 4 
Patient declined 0 0 0 0 0 0 0 0 1 3 0 0 0 0 1 3 1 3 0 0 2 7 0 0 
Patient too unwell 0 0 2 6 1 3 4 11 4 12 7 24 0 0 0 0 1 3 2 6 4 14 8 33 
Unknown 1 3 0 0 8 23 1 3 3 9 0 0 0 0 4 11 6 16 4 11 2 7 2 8 
 
 
Table 2b. Overall survival at each timepoint by questionnaire completion  
 
Timepoint Patients with missing questionnaire Patients with questionnaire 
 n Overall survival (95% CIs) n Overall survival (95% CIs) 
Week 17 13 14.6 (11.3-16.3) 61 15.8 (13.9-20.0) 
Week 23 25 14.6 (10.3-16.3) 49 16.5 (14.0-21.5) 
Week 26 23 12.7 (9.8-15.0) 51 19.1 (14.6-21.5) 
Week 39 31 12.7 (9.5-14.0) 43 19.7 (15.7-23.1) 
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Figure 1. Flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n=216) 
Excluded (n=102) 
   Not meeting inclusion criteria (n=79) 
   Declined to participate (n=19) 
   Other reasons (n=4) 
Allocated to CAP-CRT (n=36) 
 
Allocated to GEM-CRT (n=38) 
 
Randomised (n=74) 
Registered (n=114) 
Excluded (n=40) 
• Progressed (n=15) 
• Clinician choice (intolerance/surgery required 
for complications/weight loss) (n=10) 
• Patient choice (n=9) 
• Death (n=5) 
• Should not have been registered (n=1) 
 
Week 1-16 Induction GEMCAP  
Week 17-23 CAP-CRT 
 
Week 17-23 GEM-CRT 
 
Follow up at week 26, 39 and 52 
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Table 3. Mean difference in HRQL across all randomised patients between 
baseline and week 17 (induction chemotherapy) 
 
Scale n 
Wk 0 
µ 
Wk 
17 µ Diff lCI uCI 
Global 58 64.80 68.25 3.45 -1.46 8.36 
Functional       
Physical 59 79.89 78.45 -1.44 -5.94 3.06 
Role 59 70.90 69.77 -1.13 -8.43 6.17 
Emotional 59 75.71 77.68 1.98 -2.77 6.72 
Cognitive 59 82.20 78.81 -3.39 -7.64 0.86 
Social 58 65.52 70.98 5.46 -1.85 12.77 
Symptoms 
      
Fatigue 59 37.29 37.85 0.56 -6.12 7.25 
Nausea 59 14.69 12.71 -1.98 -7.69 3.73 
Pain 59 31.36 20.34 -11.02 -18.08 -3.96 
Dyspnoea 58 13.22 18.39 5.17 -1.14 11.49 
Insomnia 59 34.46 27.12 -7.34 -14.57 -0.12 
Appetite 59 36.72 23.16 -13.56 -23.90 -3.22 
Constipation 58 18.39 12.64 -5.75 -11.47 -0.03 
Diarrhoea 58 20.11 25.29 5.17 -1.75 12.10 
Financial 57 21.05 17.54 -3.51 -11.47 4.45 
Panc Pain 58 36.83 22.51 -14.32 -21.02 -7.62 
Bloating 57 32.75 22.81 -9.94 -17.03 -2.86 
Gastro 58 35.92 28.74 -7.18 -16.14 1.78 
Taste 58 27.01 32.18 5.17 -4.37 14.72 
Indigestion 56 25.60 22.02 -3.57 -12.03 4.88 
Flatulence 58 48.85 48.28 -0.57 -11.65 10.50 
Weight 58 40.80 30.46 -10.34 -20.62 -0.06 
Weak limbs 58 27.01 33.33 6.32 0.08 12.56 
Dry mouth 58 32.18 31.03 -1.15 -10.43 8.13 
Jaundice 55 16.97 11.82 -5.15 -10.96 0.66 
Bowel 58 34.48 34.77 0.29 -7.78 8.35 
Image 57 26.02 27.49 1.46 -6.78 9.70 
Side effects 49 15.65 30.61 14.97 5.38 24.55 
Future 55 58.18 47.88 -10.30 -18.78 -1.83 
Planning 57 40.35 33.92 -6.43 -17.58 4.71 
Healthcare 57 85.96 89.18 3.22 -4.28 10.71 
Sexual 43 50.00 51.94 1.94 -10.23 14.11 
Abbreviations: µ=mean; lCI=lower 95% confidence interval; uCI=upper 95% confidence interval;  Diff= 
difference between means 
NB High scores in function scales (and SatHC) represent better HRQLand higher scores in symptom scales 
represent worse HRQL. Negative differences in function scales represent HRQLworsening whereas negative 
differences in symptom scores represents HRQL improvement. Clinically significant differences are highlighted in 
bold.   
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Table 4. Mean difference in HRQL across all randomised patients between week 17 and later timepoints  
 
 
   Week 23-17 Week 26-17  Week 39-17 
Scale n Wk 17 µ Wk 23 µ Diff lCI uCI n Wk 17 µ Wk 26 µ Diff lCI uCI n Wk 17 µ Wk 39 µ Diff lCI uCI 
Functional                                     
GQOL 46 68.84 62.32 -6.52 -12.49 -0.55 46 67.39 61.96 -5.43 -12.76 1.89 37 66.44 61.71 -4.73 -11.62 2.16 
Physical 47 77.84 72.06 -5.78 -9.65 -1.91 47 78.55 76.35 -2.20 -6.95 2.55 37 76.76 74.59 -2.16 -6.88 2.55 
Role 47 70.92 63.48 -7.45 -15.66 0.77 47 69.15 64.89 -4.26 -13.85 5.34 37 66.22 63.51 -2.70 -12.01 6.61 
Emotional 47 78.55 73.17 -5.38 -10.08 -0.68 47 76.95 68.09 -8.87 -15.51 -2.22 38 77.85 68.64 -9.21 -16.49 -1.93 
Cognitive 47 80.50 77.66 -2.84 -6.96 1.29 47 79.08 75.89 -3.19 -8.65 2.27 38 76.75 74.12 -2.63 -10.22 4.96 
Social 46 69.20 65.58 -3.62 -9.33 2.08 46 66.67 64.86 -1.81 -11.72 8.10 37 63.06 63.06 0.00 -8.49 8.49 
Symptoms                                     
Fatigue 47 35.22 46.93 11.70 5.34 18.07 47 38.06 40.90 2.84 -3.53 9.20 38 40.35 37.72 -2.63 -10.39 5.12 
Nausea 47 12.06 20.21 8.16 1.17 15.14 47 13.12 15.25 2.13 -6.07 10.33 38 11.84 10.53 -1.32 -7.07 4.43 
Pain 47 20.92 24.82 3.90 -3.54 11.34 47 21.99 26.24 4.26 -4.73 13.24 38 20.61 31.58 10.96 0.52 21.41 
Dyspnoea 46 19.57 23.91 4.35 -2.12 10.82 47 20.57 24.82 4.26 -4.06 12.57 36 22.22 16.67 -5.56 -13.87 2.75 
Insomnia 47 26.24 26.24 0.00 -7.36 7.36 46 28.26 31.16 2.90 -7.50 13.30 37 27.93 28.83 0.90 -8.36 10.16 
Appetite 46 19.57 39.13 19.57 7.65 31.48 47 23.40 30.50 7.09 -2.02 16.20 37 23.42 26.13 2.70 -7.90 13.30 
Constipation 46 14.49 16.67 2.17 -4.56 8.90 46 15.94 18.12 2.17 -3.50 7.85 38 15.79 14.91 -0.88 -7.37 5.61 
Diarrhoea 47 19.86 21.99 2.13 -5.34 9.60 46 23.19 23.19 0.00 -8.85 8.85 38 21.93 21.05 -0.88 -7.37 5.61 
Financial 46 20.29 22.46 2.17 -5.18 9.52 46 18.12 23.91 5.80 -1.22 12.81 37 20.72 14.41 -6.31 -14.93 2.32 
Panc Pain 45 21.85 27.59 5.74 0.72 10.77 46 24.46 27.54 3.08 -3.03 9.19 37 22.45 30.18 7.73 -0.55 16.02 
Bloating 45 19.26 24.44 5.19 -2.50 12.87 46 25.36 25.36 0.00 -7.81 7.81 37 20.72 31.53 10.81 0.99 20.63 
Gastro 45 25.56 37.78 12.22 2.83 21.61 46 30.80 32.61 1.81 -7.59 11.22 37 27.03 23.87 -3.15 -13.62 7.31 
Taste 45 31.11 35.56 4.44 -5.48 14.37 46 36.96 36.23 -0.72 -9.70 8.25 37 29.73 24.32 -5.41 -15.04 4.22 
Indigestion 44 20.45 21.97 1.52 -8.25 11.28 43 25.58 17.83 -7.75 -16.94 1.43 37 22.52 30.63 8.11 -2.50 18.72 
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Flatulence 45 43.70 48.89 5.19 -5.69 16.06 46 47.10 42.75 -4.35 -13.59 4.89 35 53.33 49.52 -3.81 -14.84 7.22 
Weight 45 30.37 38.52 8.15 -0.16 16.46 45 29.63 34.81 5.19 -6.88 17.25 37 31.53 31.53 0.00 -9.07 9.07 
Weak limbs 45 30.37 31.85 1.48 -5.90 8.86 46 31.16 35.51 4.35 -4.89 13.59 36 33.33 30.56 -2.78 -11.46 5.91 
Dry mouth 44 28.79 27.27 -1.52 -9.38 6.35 44 29.55 26.52 -3.03 -13.70 7.64 37 28.83 22.52 -6.31 -14.93 2.32 
Jaundice 43 10.08 8.53 -1.55 -6.41 3.30 44 10.23 9.09 -1.14 -6.64 4.37 33 13.64 10.61 -3.03 -11.32 5.26 
Bowel 45 31.11 34.07 2.96 -5.12 11.04 46 35.51 40.22 4.71 -3.21 12.63 37 37.39 45.50 8.11 -0.84 17.05 
Image 45 25.93 24.81 -1.11 -7.37 5.15 45 27.78 34.07 6.30 -2.53 15.12 37 28.83 34.68 5.86 -2.55 14.26 
Side effects 45 28.15 37.78 9.63 3.36 15.90 45 34.07 33.33 -0.74 -9.41 7.93 37 35.14 30.63 -4.50 -12.86 3.85 
Future 45 48.89 57.78 8.89 -1.22 18.99 46 51.45 57.97 6.52 -3.18 16.22 37 50.45 56.76 6.31 -4.76 17.37 
Planning 44 34.09 38.64 4.55 -4.08 13.18 46 37.68 38.41 0.72 -9.81 11.26 37 38.74 42.34 3.60 -7.13 14.34 
Healthcare 45 89.63 91.48 1.85 -6.77 10.47 46 92.03 92.03 0.00 -7.60 7.60 37 92.34 84.23 -8.11 -18.96 2.74 
Sexual 36 53.70 60.65 6.94 -4.20 18.09 38 53.95 53.95 0.00 -11.32 11.32 30 49.44 58.33 8.89 -3.95 21.73 
Abbreviations: µ=mean; lCI=lower 95% confidence interval; uCI=upper 95% confidence interval; Diff= difference between means; scale abbreviations as shown in Table 1. 
NB High scores in functioning scales (and SatHC) represent better HRQL and higher scores in symptom scales represent worse HRQL. Negative differences in functioning scales (and SatHC) 
represent HRQLworsening whereas negative differences in symptom scores represent HRQLimprovement. Clinically significant differences are highlighted in bold. 
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Table 5. Difference in HRQL between week 17 and later timepoints by trial arm 
 
  
Week 23-Week 17 Week 26-Week 17 Week 39-Week 17 
  
Capecitabine Gemcitabine 
    Capecitabine Gemcitabine     Capecitabine Gemcitabine     
Scale 
Median 
score 
week 17 n 
Median 
difference in 
score (range) 
Median 
score 
week 17 n 
Median 
difference in 
score (range) z p n 
Median 
difference in 
score (range)  n 
Median 
difference in 
score (range) z p n 
Median 
difference in 
score (range) n 
Median 
difference in 
score (range) z p 
Func.  
    
 
                                
GQOL 66.7 23 
0.0  
(-33.3,41.7) 66.7 23 
-16.7  
(50.0,33.3) 1.70 0.090 23 
0.0  
(-50.0,50.0) 23 
0.0  
(-83.3,33.3) 0.57 0.571 23 
0.0  
(-41.7,33.3) 14 
-8.3  
(-58.3,33.3) 1.21 0.227 
Physical 86.7 23 
0.0  
(-40.0,26.7) 73.3 24 
-10.0  
(-33.3,20.0) 1.58 0.114 23 
0.0  
(-33.3,26.7) 24 
0.0  
(-66.7,26.7) -0.24 0.808 22 
0.0  
(-13.3,26.7) 15 
-6.7  
(-40.0,13.3) 1.28 0.199 
Role 83.3 23 
0.0  
(-50.0,66.7) 66.7 24 
-16.7  
(-66.7,66.7) 1.11 0.268 23 
0.0  
(-50.0,66.7) 24 
-16.7  
(-100.0,66.7) 1.13 0.259 22 
0.0  
(-50.0,50.0) 15 
0.0  
(-66.7,33.3) 1.22 0.223 
Emotional 83.3 23 
0.0  
(-58.3,16.7) 75.0 24 
0.0  
(-58.3,25.0) -0.17 0.869 23 
0.0  
(-33.3,25.0) 24 
-8.3  
(-83.3,41.7) 1.67 0.094 23 
-8.3  
(-50.0,16.7) 15 
-8.3  
(-75.0,50.0) 0.53 0.598 
Cognitive 83.3 23 
0.0  
(-16.7,16.7) 83.3 24 
0.0  
(-33.3,33.3) 2.10 0.036 23 
0.0  
(-33.3,33.3) 24 
0.0  
(-66.7,16.7) 1.19 0.233 23 
0.0  
(-66.7,33.3) 15 
-16.7  
(-50.0,33.3) 2.54 0.011 
Social 83.3 23 
0.0  
(-66.7,50.0) 66.7 23 
0.0 
(-33.3,33.3) 0.19 0.848 23 
0.0  
(-66.7,66.7) 23 
0.0  
(-100.0,33.3) 0.80 0.422 23 
0.0  
(-66.7,50.0) 14 
0.0  
(-66.7,33.3) -0.02 0.987 
Symp.  
    
 
                                
Fatigue 33.3 23 
11.1  
(-33.3,44.4) 33.3 24 
16.7  
(-33.3,55.6) -1.99 0.046 23 
0.0  
(-44.4,33.3) 24 
0.0  
(-33.3,77.8) -0.45 0.652 23 
-11.1  
(-66.7,33.3) 15 
-11.1  
(-22.2,44.4) -1.47 0.142 
Nausea 0.0 23 
0.0  
(-33.3,50.0) 16.7 24 
8.3  
(-50.0,83.3) -1.00 0.320 23 
0.0  
(-33.3,50.0) 24 
0.0  
(-66.7,100.0) 0.38 0.700 23 
0.0  
(-33.3,50.0) 15 
0.0  
(-33.3,0.0) 1.83 0.067 
Pain 16.7 23 
0.0  
(-33.3,33.3) 16.7 24 
0.0  
(-66.7,83.3) -1.36 0.174 23 
0.0  
(-50.0,66.7) 24 
0.0  
(-66.7,100.0) -0.79 0.431 23 
0.0  
(-66.7,66.7) 15 
16.7  
(-50.0,66.7) -0.61 0.545 
Dyspnoea 0.0 22 
0.0  
(-66.7,33.3) 33.3 24 
0.0  
(-33.3,66.7) -1.52 0.129 23 
0.0  
(-66.7,66.7) 24 
0.0  
(-33.3,66.7) -1.19 0.234 21 
0.0  
(-66.7,33.3) 15 
0.0  
(-33.3,66.7) -1.38 0.167 
Insomnia 33.3 23 
0.0  
(-66.7,33.3) 0.0 24 
0.0  
(-33.3,66.7) -0.48 0.635 22 
0.0  
(-66.7,33.3) 24 
0.0  
(-66.7,100.0) 0.12 0.907 22 
0.0  
(-66.7,66.7) 15 
0.0 
 (-33.3,66.7) -0.96 0.335 
Appetite 0.0 23 
0.0  
(-66.7,100.0) 33.3 23 
33.3  
(-66.7,100.0) -1.75 0.081 23 
0.0  
(-66.7,100.0) 24 
0.0  
(-33.3,66.7) -0.80 0.421 22 
0.0 
 (-33.3,100.0) 15 
0.0  
(-66.7,66.7) 0.12 0.904 
Constipation 0.0 22 
0.0  
(-33.3,66.7) 0.0 24 
0.0  
(-33.3,33.3) -0.64 0.525 22 
0.0  
(-33.3,33.3) 24 
0.0  
(-33.3,33.3) -0.65 0.516 23 
0.0 
 (-66.7,33.3) 15 
0.0  
(-33.3,33.3) -0.66 0.511 
Diarrhoea 0.0 23 
0.0  
(-33.3,33.3) 33.3 24 
0.0  
(-66.7,66.7) 0.42 0.678 22 
0.0  
(-33.3,66.7) 24 
0.0  
(-66.7,66.7) 0.03 0.980 23 
0.0  
(-33.3,33.3) 15 
0.0 
 (-33.3,33.3) -0.21 0.831 
Financial 0.0 23 
0.0  
(-33.3,33.3) 0.0 23 
0.0  
(-33.3,100.0) -1.12 0.262 23 
0.0  
(-33.3,66.7) 23 
0.0  
(-33.3,66.7) -0.87 0.383 23 
0.0  
(-66.7,66.7) 14 
0.0  
(-66.7,33.3) 0.51 0.613 
Panc Pain 8.3 23 
0.0  
(-33.3,33.3) 25.0 22 
8.3  
(-16.7,50.0) -0.47 0.640 23 
0.0  
(-41.7,50.0) 23 
0.0  
(-33.3,50.0) 0.13 0.894 22 
8.3  
(-50.0,58.3) 15 
0.0 
 (-33.3,75.0) 0.19 0.851 
Bloating 0.0 23 
0.0  
(-33.3,33.3) 33.3 22 
0.0  
(-33.3,100.0) -2.11 0.035 23 
0.0  
(-33.3,33.3) 23 
0.0  
(-66.7,66.7) -0.62 0.536 22 
0.0  
(-66.7,100.0) 15 
0.0  
(-33.3,33.3) 0.42 0.674 
Gastro 16.7 23 
0.0  
(-16.7,100.0) 33.3 22 
8.3 (-
50.0,66.7) -0.36 0.718 23 
0.0  
(-66.7,66.7) 23 
0.0  
(-50.0,100.0) 0.35 0.726 22 
0.0 
 (-66.7,66.7) 15 
-16.7  
(-50.0,50.0) 1.66 0.097 
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Taste 33.3 23 
0.0  
(-100.0,66.7) 33.3 22 
0.0 (-
33.3,100.0) -0.91 0.361 23 
0.0  
(-66.7,66.7) 23 
0.0  
(-66.7,66.7) -0.60 0.546 22 
0.0  
(-66.7,33.3) 15 
0.0  
(-66.7,33.3) -0.34 0.732 
Indigestion 0.0 22 
0.0  
(-33.3,100.0) 33.3 22 
0.0  
(-33.3,66.7) 0.11 0.915 21 
0.0  
(-100.0,66.7) 22 
0.0  
(-66.7,33.3) 1.17 0.244 22 
0.0  
(-66.7,100.0) 15 0.0 (0.0,33.3) -0.45 0.651 
Flatulence 33.3 23 
0.0  
(-33.3,100.0) 33.3 22 
0.0  
(-100,100) -0.01 0.990 23 
0.0  
(-100.0,66.7) 23 
0.0  
(-66.7,33.3) 0.30 0.761 21 
0.0  
(-66.7,100.0) 14 
0.0  
(-33.3,33.3) 0.19 0.852 
Weight 33.3 23 
0.0  
(-33.3,66.7) 33.3 22 
0.0  
(-66.7,66.7) -1.02 0.310 22 
0.0  
(-66.7,66.7) 23 
0.0  
(-100,100) -0.73 0.467 22 
0.0  
(-33.3,66.7) 15 
0.0  
(-66.7,66.7) 0.34 0.738 
Weak limbs 33.3 23 
0.0  
(-66.7,33.3) 33.3 22 
0.0  
(-33.3,66.7) -1.76 0.078 23 
0.0  
(-66.7,33.3) 23 
0.0  
(-33.3,100.0) -1.37 0.169 21 
0.0  
(-33.3,33.3) 15 
0.0 
 (-33.3,66.7) -1.62 0.104 
Dry mouth 33.3 22 
0.0 
 (-66.7,33.3) 33.3 22 
0.0  
(-66.7,33.3) -2.18 0.029 22 
0.0  
(-66.7,66.7) 22 
0.0  
(-66.7,100.0) -1.23 0.220 22 
0.0  
(-66.7,0.0) 15 
0.0  
(-33.3,33.3) -3.44 0.001 
Jaundice 0.0 22 
0.0  
(-33.3,50.0) 0.0 21 
0.0  
(-50.0,33.3) 0.62 0.536 22 
0.0  
(-50.0,66.7) 22 
0.0  
(-33.3,16.7) -0.05 0.956 19 
0.0  
(-66.7,50.0) 14 
0.0 
 (-66.7,33.3) -0.12 0.907 
Bowel 33.3 23 
0.0  
(-33.3,66.7) 50.0 22 
0.0  
(-50.0,66.7) 1.02 0.306 23 
0.0  
(-50.0,66.7) 23 
0.0  
(-50.0,50.0) -0.45 0.652 22 
0.0  
(-50.0,66.7) 15 
0.0 
 (-33.3,50.0) 0.00 1.000 
Image 33.3 23 
0.0  
(-33.3,50.0) 0.0 22 
0.0  
(-66.7,33.3) 0.51 0.608 23 
0.0  
(-50.0,50.0) 22 
0.0  
(-50.0,100.0) -0.28 0.778 22 
0.0  
(-50.0,33.3) 15 
0.0 
 (-16.7,66.7) -2.29 0.022 
Side effects 33.3 23 
0.0  
(-33.3,33.3) 33.3 22 
0.0 (-
33.3,66.7) -0.55 0.584 23 
0.0  
(-66.7,33.3) 22 
0.0  
(-33.3,100.0) -0.15 0.883 22 
0.0  
(-33.3,33.3) 15 
0.0  
(-33.3,33.3) -0.02 0.987 
Future 66.7 23 
0.0  
(-33.3,66.7) 33.3 22 
0.0  
(-66.7,100.0) -0.32 0.747 23 
0.0  
(-33.3,66.7) 23 
0.0  
(-33.3,100.0) -2.13 0.033 22 
0.0  
(-33.3,100.0) 15 
0.0 
 (-66.7,66.7) -0.52 0.600 
Planning 33.3 23 
0.0  
(-33.3,66.7) 33.3 21 
0.0  
(-33.3,66.7) 0.20 0.841 23 
0.0  
(-100.0,66.7) 23 
0.0  
(-66.7,66.7) -0.85 0.396 22 
0.0  
(-66.7,100.0) 15 
0.0  
(-33.3,66.7) -0.80 0.426 
Healthcare 100.0 23 
0.0  
(-100,100) 100.0 22 
0.0  
(-16.7,83.3) -0.76 0.449 23 
0.0 (-
100.0,100.0) 23 
0.0  
(-33.3,50.0) -0.25 0.803 22 
0.0  
(-100.0,16.7) 15 
0.0  
(-50.0,50.0) -1.91 0.056 
Sexual 41.7 20 
0.0 
(-66.7,66.7) 66.7 16 
0.0  
(-100.0,83.3) -0.07 0.941 20 0.0 (0.0,66.7) 18 
0.0  
(-100.0,83.3) 1.24 0.213 17 
0.0  
(-33.3,33.3) 13 
0.0  
(-100.0,83.3) -0.55 0.583 
 
 
NB: Negative differences in functioning scales (and SatHC) represent HRQL worsening whereas negative differences in symptom scores represents HRQL improvement. Abbreviations as 
shown in Table 1.  P values < 0.05 are in bold. 
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Table 6. Mean week 23 QLQ-PAN26 scale scores by those with and without any CTCAE grade 3 or 4 adverse events during CRT 
 
 PAN 26 scale No grade 3 or 4 adverse events during CRT Any Grade 3 or 4 adverse events during CRT 
  n Mean Lower 95% CI Upper 95% CI n Mean Lower 95% CI Upper 95% CI 
Pancreatic pain* 38 23.90 16.93 30.88 10 36.67 18.20 55.14 
Bloating* 38 20.18 11.52 28.83 10 36.67 15.79 57.55 
Gastrointestinal* 38 32.89 21.40 44.39 10 58.33 35.68 80.99 
Taste loss 38 34.21 24.19 44.24 10 40.00 10.69 69.31 
Indigestion 38 21.05 11.38 30.73 10 23.33 0.71 45.95 
Flatulence 38 45.61 34.98 56.25 10 50.00 26.83 73.17 
Weight* 38 31.58 20.20 42.96 10 63.33 32.65 94.01 
Weak limbs* 38 26.32 17.43 35.20 10 53.33 30.30 76.37 
Dry mouth 37 28.83 18.63 39.03 10 23.33 3.70 42.96 
Jaundice 38 7.89 2.84 12.95 10 8.33 2.05 14.62 
Altered bowel habit* 38 28.51 18.41 38.61 10 58.33 33.67 82.99 
Poor body image 38 25.44 14.80 36.07 10 25.00 3.05 46.95 
Side effects of treatment 38 35.96 27.37 44.56 10 36.67 12.95 60.38 
Future health concern* 38 51.75 39.89 63.62 10 73.33 48.71 97.96 
Forward planning limited* 37 33.33 21.91 44.75 10 56.67 37.04 76.30 
Satisfaction with healthcare 38 92.11 85.52 98.69 10 91.67 81.53 101.80 
Sexual dissatisfaction 31 59.14 43.45 74.83 7 66.67 32.20 101.13 
 *indicates a difference in means of more than 10 points 
  
